This knowledge would help identify individuals who could benefit from early detection programmes, which are essential for a tumour with low survival rates because it is almost always detected late.

Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570), which has recently been granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a novel, gut-restricted PHD inhibitor developed with Pharma.AI, Insilico’s generative platform, for the treatment of Inflammatory Bowel Disease (IBD). 

New research shows that adolescents who were overweight, struggled to make friends, were born outside the U.S., or faced mental health challenges such as anxiety, depression, ADD/ADHD or learning disabilities were at greater risk of involvement in bullying, either as victims, perpetrators or both. The findings reveal a troubling cycle, underscoring the need for prevention efforts that address the social, family, and health-related factors shaping adolescent behavior.